The independent source for health policy research, polling, and news.
561-580 of 706 results
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the possible impact of the tax bill on the Medicare program, confirmation hearings for a new secretary of Health and Human Services and the future of the Children’s Health Insurance Program. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
The price for Pfizer’s Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Alice Ollstein of Talking Points Memo and Sarah Jane Tribble of Kaiser Health News discuss some of the under-covered health stories of the past several weeks, including drug price issues, the opioid epidemic and women’s reproductive health.
In an effort to reduce drug costs and increase efficiency, Massachusetts is seeking federal approval to implement a new approach to how the state’s Medicaid program covers prescription medications.
Medicare is examining how rebates and discounts could be shared in some way with Part D beneficiaries to reduce their out-of-pocket costs.
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor’s office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
© 2026 KFF